Veru reports Q3 EPS (50c) vs. (75c) last year

Cash, cash equivalents, and restricted cash were $15.0M as of June 30, 2025 versus $24.9M as of September 30, 2024. “We have now reported all the positive efficacy and safety topline results from our Phase 2b QUALITY and Maintenance Extension study, and are looking forward to FDA feedback on the regulatory pathway for enobosarm to be used as an adjunctive therapy with GLP-1 RA to preserve lean mass while burning more fat for chronic weight loss management,” said CEO Mitchell Steiner. “The efficacy and safety of Veru‘s (VERU) oral agent enobosarm looks better than any of the injectable myostatin inhibitors now under development by our competitors. Unlike our competitors, enobosarm has positive physical function data measured by stair climb power. Furthermore, we have strengthened our intellectual property position with the selection of a novel modified release oral enobosarm formulation confirmed in a clinical pharmacokinetic study.”